La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Givaudan a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Givaudan..

Givaudan (OTC:GVDNY) Azioni, Catena delle Opzioni

Givaudan

GIVAUDAN SA ADR

Spun off from Roche in 2000, Givaudan is one of the world's leading flavor and fragrance manufacturers, with a presence in more than 80 countries. It sources more than 11,000 different ingredients from over 100 countries. The company serves end consumer markets with fragrances for personal, home, and laundry care brands, including prestige perfumes. In flavors, customers are in beverages, savory, snacks, sweet goods, and dairy. Givaudan has nearly 10,000 employees, and its perfumery team is the largest in the industry.

Givaudan SA

Givaudan SA (OTC: <a class="ticker" href="https://www.benzinga.com/stock/gvdny#OTC">GVDNY</a>) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company&#39;s changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Givaudan is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That&#39;s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For Givaudan, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Earnings Estimate Revisions for Givaudan
This company is expected to earn $2.59 per share for the fiscal year ending December 2024, which represents a year-over-year change of 19.9%.
Analysts have been steadily raising their estimates for Givaudan. Over the past three months, the Zacks Consensus Estimate for the company has increased 5.3%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of Givaudan to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2293857/what-makes-givaudan-gvdny-a-new-strong-buy-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2293857">To read this article on Zacks.com click here.</a>

Earnings

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

GVDNY

What Makes Givaudan a New Strong Buy Stock

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>According to Deutsche Bank, the prior rating for Encompass Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) was changed from Hold to Buy. In the first quarter, Encompass Health showed an EPS of $1.05, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $89.68 and a 52-week-low of $59.10. At the end of the last trading period, Encompass Health closed at $79.76.</li>
<li>According to Kepler Cheuvreux, the prior rating for ABB Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABB#NYSE">ABB</a>) was changed from Hold to Buy. ABB earned $0.26 in the first quarter, compared to $0.30 in the year-ago quarter. The current stock performance of ABB shows a 52-week-high of $35.28 and a 52-week-low of $23.06. Moreover, at the end of the last trading period, the closing price was at $33.96.</li>
<li>Berenberg upgraded the previous rating for Informa PLC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFJPY#OTC">IFJPY</a>) from Hold to Buy. The stock has a 52-week-high of $16.19 and a 52-week-low of $9.18. At the end of the last trading period, Informa closed at $14.13.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>Deutsche Bank downgraded the previous rating for Atotech Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATC#NYSE">ATC</a>) from Buy to Hold. In the first quarter, Atotech earned $0.55. The stock has a 52-week-high of $26.67 and a 52-week-low of $17.00. At the end of the last trading period, Atotech closed at $25.09.</li>
<li>According to CL King, the prior rating for Welbilt Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBT#NYSE">WBT</a>) was changed from Buy to Neutral. Welbilt earned $0.08 in the first quarter, compared to $0.01 in the year-ago quarter. The current stock performance of Welbilt shows a 52-week-high of $25.19 and a 52-week-low of $5.21. Moreover, at the end of the last trading period, the closing price was at $23.40.</li>
<li>According to UBS, the prior rating for Rightmove PLC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RTMVY#OTC">RTMVY</a>) was changed from Buy to Neutral. The stock has a 52-week-high of $18.61 and a 52-week-low of $13.35. At the end of the last trading period, Rightmove closed at $18.07.</li>
<li>According to Societe Generale, the prior rating for Pennon Group PLC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PEGRY#OTC">PEGRY</a>) was changed from Buy to Hold. The current stock performance of Pennon Group shows a 52-week-high of $34.42 and a 52-week-low of $25.88. Moreover, at the end of the last trading period, the closing price was at $31.34.</li>
<li>For ContextLogic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISH#NASDAQ">WISH</a>), Evercore ISI Group downgraded the previous rating of Outperform to In-Line. Interestingly, in the first quarter, ContextLogic&#39;s EPS was $0.21. The stock has a 52-week-high of $32.85 and a 52-week-low of $0.38. At the end of the last trading period, ContextLogic closed at $12.24.</li>
<li>According to Barclays, the prior rating for Keysight Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) was changed from Overweight to Equal-Weight. In the second quarter, Keysight Technologies showed an EPS of $1.44, compared to $0.78 from the year-ago quarter. The stock has a 52-week-high of $155.88 and a 52-week-low of $90.62. At the end of the last trading period, Keysight Technologies closed at $153.56.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>Keefe, Bruyette &amp; Woods initiated coverage on UWM Holdings Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Market Perform rating. The price target for UWM Holdings is set to $8.50. In the first quarter, UWM Holdings earned $0.33. The current stock performance of UWM Holdings shows a 52-week-high of $12.45 and a 52-week-low of $6.25. Moreover, at the end of the last trading period, the closing price was at $8.22.</li>
<li>Citigroup initiated coverage on Vintage Wine Estates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) with a Buy rating. The price target for Vintage Wine Estates is set to $14.00. The current stock performance of Vintage Wine Estates shows a 52-week-high of $13.48 and a 52-week-low of $11.40. Moreover, at the end of the last trading period, the closing price was at $11.87.</li>
<li>With an Overweight rating, Cantor Fitzgerald initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>). The price target seems to have been set at $71.00 for Arcturus Therapeutics. In the first quarter, Arcturus Therapeutics showed an EPS of $2.15, compared to $0.67 from the year-ago quarter. The stock has a 52-week-high of $129.71 and a 52-week-low of $24.87. At the end of the last trading period, Arcturus Therapeutics closed at $35.94.</li>
<li>With a Buy rating, Ladenburg Thalmann initiated coverage on Harrow Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>). The price target seems to have been set at $14.25 for Harrow Health. In the first quarter, Harrow Health showed an EPS of $0.01, compared to $0.50 from the year-ago quarter. The stock has a 52-week-high of $11.24 and a 52-week-low of $4.65. At the end of the last trading period, Harrow Health closed at $9.09.</li>
<li>With a Buy rating, Berenberg initiated coverage on Renalytix PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>). The price target seems to have been set at $38.00 for Renalytix. Interestingly, in the third quarter, Renalytix&#39;s EPS was $0.12. At the moment, the stock has a 52-week-high of $35.71 and a 52-week-low of $9.91. Renalytix closed at $29.94 at the end of the last trading period.</li>
<li>CICC initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with an Outperform rating. The price target for Connect Biopharma Hldgs is set to $27.00. The current stock performance of Connect Biopharma Hldgs shows a 52-week-high of $23.29 and a 52-week-low of $14.02. Moreover, at the end of the last trading period, the closing price was at $19.80.</li>
<li>Raymond James initiated coverage on BRP Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) with a Strong Buy rating. In the first quarter, BRP showed an EPS of $2.01, compared to $0.19 from the year-ago quarter. The current stock performance of BRP shows a 52-week-high of $96.44 and a 52-week-low of $40.03. Moreover, at the end of the last trading period, the closing price was at $78.40.</li>
<li>Raymond James initiated coverage on Camping World Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) with an Outperform rating. The price target for Camping World Holdings is set to $45.00. In the first quarter, Camping World Holdings showed an EPS of $1.40, compared to $0.03 from the year-ago quarter. The current stock performance of Camping World Holdings shows a 52-week-high of $48.50 and a 52-week-low of $22.60. Moreover, at the end of the last trading period, the closing price was at $41.37.</li>
<li>For Winnebago Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>), Raymond James initiated coverage, by setting the current rating at Market Perform. Winnebago Industries earned $2.16 in the third quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Winnebago Industries shows a 52-week-high of $87.53 and a 52-week-low of $44.33. Moreover, at the end of the last trading period, the closing price was at $70.44.</li>
<li>For Thor Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>), Raymond James initiated coverage, by setting the current rating at Underperform. Thor Industries earned $3.29 in the third quarter, compared to $0.43 in the year-ago quarter. The current stock performance of Thor Industries shows a 52-week-high of $152.20 and a 52-week-low of $78.64. Moreover, at the end of the last trading period, the closing price was at $116.20.</li>
<li>With an Overweight rating, Stephens &amp; Co. initiated coverage on HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>). The price target seems to have been set at $100.00 for HealthEquity. HealthEquity earned $0.38 in the first quarter, compared to $0.43 in the year-ago quarter. The stock has a 52-week-high of $93.32 and a 52-week-low of $45.82. At the end of the last trading period, HealthEquity closed at $81.09.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Downgrades

Initiation

Intraday Update

ARCT

BTDPY

CNTB

DOCRF

DOOO

HROW

IFJPY

IIPR

KEYS

NGLOY

PEGRY

RNLX

RTMVY

UWMC

Vintage Wine Estates, Inc. - Common Stock

WISH

Benzinga's Top Ratings Upgrades, Downgrades For July 2, 2021

Goldman Sachs upgrades Givaudan (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GVDNY#OTC">GVDNY</a>) from Sell to Neutral.

Comments

Givaudan

Givaudan (GVDNY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO